Catalyst Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY Revenue (est.)
$636.2Mnext fiscal year
FY EPS (est.)
$3.17next fiscal year
Monitoring Framework
Key Performance Indicators
FIRDAPSE Net Product Revenue Quarterly98.9M
AGAMREE Net Product Revenue Quarterly36.7M
FYCOMPA Net Product Revenue Quarterly13.8M
Total Product Revenue, net Quarterly149.3M
Watch Items
- Shareholder Vote on Angelini Pharma MergerTrigger: Majority of outstanding shares voting in favorAction: Monitor the outcome of the virtual special meeting of stockholders scheduled for July 8, 2026.
- Regulatory Approvals and Antitrust ClearanceTrigger: Expiration or termination of the waiting period under the HSR ActAction: Track filings and approvals from the FTC and DOJ to ensure no regulatory blocks prevent the merger.
- FIRDAPSE Patent Settlement ImplementationTrigger: Submission of the confidential settlement agreement to the FTC and DOJAction: Verify that the settlement with Hetero Labs remains intact, securing exclusivity through January 2035.
Research as of 20 Jun 2026